Researchers from university of Alabama find that statins may hinder the body’s ability to repair muscles. It is worth mentioning that millions of people take statins to lower cholesterol.
Fatigue is considered the most frequently reported side effect of statin therapy with 9 percent of patients reporting muscle pain. The effects become more pronounced as the doses of the medication and physical activity are increased. These side effects are quite common in people who use statins.
Lead researcher Anna Thalacker-Mercer stated: “The research is based on preliminary data and more research is definitely required to find out the more precise link. However, the results indicate that statins cause some serious side effects that alter the ability of skeletal muscle to repair.”
Read the rest of this entry
A recent study which is soon going to be published in the April issue of the journal “Diabetes Care”, published by the “American Diabetes Association”, has come up with alarming news for those suffering from diabetes. According to it, diabetes also affects the lung capacity thus carrying repercussion on the prospective use of inhaled insulin.
The issue also emphasizes the need for more consistent efforts to control lipids to reduce cardiometabolic risk. It also focuses for the first time on the need to test for and treat high levels of apolipoprotein B, a protein which plays an important role in causing heart disease (atherosclerosis). It has been evidently proven that levels of this protein are a better indicator of heart disease risk than total cholesterol or LDL (“bad cholesterol”).
As a part of a larger investigation known as the ‘Atherosclerosis Risk in Communities (ARIC)’ study, the lung study has affirmed the previous link between diabetes and increase in lung abnormalities. The same researchers in the previous researches have confirmed that downfall in lung capacity could be an indicator towards onset of diabetes. The editorial also credits the downfall in the lung capacity to the diabetes mortality and morbidity.
Read the rest of this entry
